This is the first of a three-part blog series that will focus on the challenges of volume and viscosity in drug delivery.
Since the 1990s, there has been an increased focus within the pharmaceutical industry on the growth and business opportunities for biologic drug products. With biologics expected to account for 50% of global drug spend by 2020, the value of each therapeutic dose is significant. This can be attributed to the complexity of the protein-based drug and also the manner in which the drug needs to be administered. Prefillable syringe systems (PFS) are the preferred delivery method for biologics, which tend to be unsuitable for oral delivery.